Celldex Therapeutics (NASDAQ:CLDX) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $21.58 and traded as high as $27.44. Celldex Therapeutics shares last traded at $26.47, with a volume of 964,066 shares traded.

Analyst Ratings Changes

Several research firms recently commented on CLDX. Barclays began coverage on shares of Celldex Therapeutics in a research report on Monday. They issued an “underweight” rating and a $25.00 price objective on the stock. HC Wainwright decreased their price objective on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $62.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. Finally, Wells Fargo & Company decreased their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 20th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.78.

Celldex Therapeutics Trading Down 2.4%

The firm’s 50 day moving average is $24.21 and its two-hundred day moving average is $21.58. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -8.79 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.13 million. As a group, equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB raised its stake in Celldex Therapeutics by 2.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock valued at $440,000 after purchasing an additional 500 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after acquiring an additional 680 shares during the last quarter. AlphaQuest LLC increased its stake in shares of Celldex Therapeutics by 7.0% during the 2nd quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 844 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in shares of Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 881 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.